Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy

A groundbreaking international trial has demonstrated that a genomic test can help millions of women with hormone-positive breast cancer avoid chemotherapy without compromising their outcomes. The Optima trial, involving over 4,000 patients from the UK, Norway, Sweden, Australia, New Zealand, and Thailand, found that patients with a low genomic test score could be safely treated with hormone therapy alone. This approach could spare many patients from the toxic side effects of chemotherapy, such as hair loss, nausea, fatigue, infertility, and cognitive impairment. The genomic test, known as the Prosigna test, analyzes the activity of 50 genes in tumor tissue to determine the molecular subtype of breast cancer and assess the risk of recurrence. By using tumor biology rather than traditional clinical features alone, the test enables more personalized treatment decisions. The trial’s chief investigator, Professor Rob Stein of University College London, highlighted that the findings address a longstanding challenge in breast cancer care by identifying who truly benefits from chemotherapy and who does not. The results, to be presented at the American Society of Clinical Oncology’s annual meeting, could transform global healthcare guidelines by reducing unnecessary chemotherapy treatments. For patients, this means avoiding the physical and emotional burdens associated with chemotherapy, while health systems may benefit from more efficient and evidence-based use of resources. One participant described the relief of skipping chemotherapy as feeling “like Christmas,” underscoring the significant impact on quality of life. This advancement marks a major step toward personalized medicine in breast cancer treatment, offering hope for improved patient outcomes and reduced treatment-related harm. As breast cancer remains the most common cancer worldwide, the implementation of genomic testing could reshape standard care practices and improve the lives of millions of women globally.